Key result
Three of 15 tested antiviral compounds were highly active against four strains of enterovirus D68 in vitro, with 50% effective concentrations ranging from 0.0012 to 0.027 μM.
Effect estimate: 50% effective concentrations of 0.0012 to 0.027 μM
Three antiviral compounds demonstrated high in vitro efficacy against multiple strains of enterovirus D68, warranting further in vivo investigation.
No clinical role yet; leaves open in vivo testing for enterovirus D68 antivirals.
In 2014, the United States experienced a large outbreak of severe respiratory illness associated with enterovirus D68 (EV-D68). We used a homogeneous, cell-based assay to assess the antiviral activity of compounds developed for EV/rhinovirus infection or other indications. Three of 15 compounds were highly active against all four strains tested (the prototype and three 2014 strains), with 50% effective concentrations of 0.0012 to 0.027 μM. Additional studies are needed to assess their in vivo efficacy against EV-D68.
No takes yet. Share an insight, caveat, or question.
Rhoden et al. (2015) studied Enterovirus D68 infection. Antiviral compounds was evaluated on Antiviral activity (50% effective concentrations) (50% effective concentrations of 0.0012 to 0.027 μM). Three of 15 tested antiviral compounds were highly active against four strains of enterovirus D68 in vitro, with 50% effective concentrations ranging from 0.0012 to 0.027 μM.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: